Ermium Therapeutics is developing orally available drug candidates allowing the efficient control of type 1 interferons.
These drug candidates have the potential to address a wide range of chronic auto-immune diseases, affecting millions of people worldwide and include type I interferon-mediated diseases.
In response to an unknown trigger, the immune system may attack the body’s own tissues weakening . Treatment for autoimmune diseases generally focuses on reducing immune system activity.
There are more than 80 autoimmune diseases. While some are well known and include for instance Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel diseases, Multiple sclerosis and type 1 diabetes mellitus, other are rare and difficult to diagnose.
The world prevalence of auto-immune diseases is increasing and they affect up to 10% of the population in Europe and North America.
Most of these diseases have no cure and the most serious conditions require lifelong treatment to ease symptoms.